通过
体内和体外解决方案书写抗体发现服务的未来
Twist 在抗体发现、使用合成文库展示噬菌体、通过免疫动物进行体内发现以及 AI 辅助的抗体工程方面具有丰富的一体化专业知识。
Learn more about this industry leading,
end-to-end antibody discovery solution that leverages comprehensive in vivo,
in vitro and in silico antibody discovery and engineering services.
久经考验的团队和成功的业绩档案
您可以放心地与 Twist 和 Abveris 合作来满足您的抗体发现需求。Twist 在 110 多个活跃项目中拥有 278 个合作伙伴，而 Abveris 拥有 100 多个成功的研发活动、超过 7 个临床试验的合作伙伴项目，而且超过 80% 的合作伙伴再次合作开展其他项目。
完全验证和功能目标的对外许可产品线
客户评语
查看我们目前正在进行的项目类型，并分享我们如何在任一阶段支持您的抗体发现项目。
联系我们
与 Twist Bioscience 合作，满足您的所有抗体发现需求。
About Twist Biopharma (The Biologics Discovery and Optimization Division of
Twist Bioscience)
Twist Biopharma combines high-throughput DNA synthesis technology, deep expertise in antibody engineering and in vivo, in vitro and in silico discovery methods to provide end-to-end antibody discovery solutions across the preclinical continuum and tailored to our partner’s specific needs. By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries with discovery beginning with either in vivo or in vitro diversity. Our Library of Libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. Additionally, in vivo discovery approaches including single B cell screening and hybridoma discovery enable parallel paths where multiple technology methods can be leveraged to create a panel of highly diverse antibody leads. Our automated screening and panning processes enable us to identify high affinity leads that our partners can move forward into the clinic. We also offer supporting development capabilities, including IgG conversion, expression, purification, biophysical characterization, and functional characterization.
